Cas:132991-24-3 4-[(4-tert-butylphenoxy)methyl]benzoic acid manufacturer & supplier

Chemical Name:4-[(4-tert-butylphenoxy)methyl]benzoic acid

CAS.NO:132991-24-3

Synonyms:4-[(4-tert-butylphenoxy)methyl]benzoic acid

Molecular Formula:C₁₈H₂₀O₃

Molecular Weight:284.35000

HS Code:2918990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:46.53000

Exact Mass:284.14100

LogP:4.26130

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-[(4-tert-butylphenoxy)methyl]benzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-[(4-tert-butylphenoxy)methyl]benzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-[(4-tert-butylphenoxy)methyl]benzoic acid Use and application,4-[(4-tert-butylphenoxy)methyl]benzoic acid technical grade,usp/ep/jp grade.

Related News: Russia, which shares a 2,600-mile border with China, reported its first two coronavirus cases on Friday. 4-[(4-tert-butylphenoxy)methyl]benzoic acid manufacturer Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Novavax president and CEO Stanley Erck said in a statement. “These clinical results reinforce that [the vaccine] is extremely effective and offers complete protection against both moderate and severe COVID-19 infection. 4-[(4-tert-butylphenoxy)methyl]benzoic acid supplier More than 2,000 new cases were also recorded in the country in the past 24 hours, raising the worldwide total to nearly 14,380, according to Chinese and World Health Organization data. The vast majority of the cases are inside China; about 100 cases have been confirmed in at least 23 other countries. 4-[(4-tert-butylphenoxy)methyl]benzoic acid vendor Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. 4-[(4-tert-butylphenoxy)methyl]benzoic acid factory Capacity: the bottleneck of business growth, expanding capacity and increasing utilization become a trend. Capacity is the core factor that determines the supply capacity of API companies. Insufficient capacity will cause companies to selectively complete orders and produce varieties, limiting the expansion of API products and market development.